[1]王建华.R-CHOP方案治疗B细胞非霍奇金淋巴瘤与CHOP方案对比的Meta分析[J].医学信息,2019,32(10):81-84.[doi:10.3969/j.issn.1006-1959.2019.10.027]
　WANG Jian-hua.Meta-analysis of R-CHOP Regimen in the Treatment of B-cell Non-Hodgkin's Lymphoma Versus CHOP Regimen[J].Journal of Medical Information,2019,32(10):81-84.[doi:10.3969/j.issn.1006-1959.2019.10.027]
点击复制

R-CHOP方案治疗B细胞非霍奇金淋巴瘤与CHOP方案对比的Meta分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年10期
页码:
81-84
栏目:
论著
出版日期:
2019-05-15

文章信息/Info

Title:
Meta-analysis of R-CHOP Regimen in the Treatment of B-cell Non-Hodgkin's Lymphoma Versus CHOP Regimen
文章编号:
1006-1959（2019）10-0081-04
作者:
王建华
（内蒙古医科大学第三附属医院/内蒙古包钢医院血液科，内蒙古 包头 014010）
Author(s):
WANG Jian-hua
(The Third Affiliated Hospital of Inner Mongolia Medical University/Department of Hematology,Inner Mongolia Baotou Steel Hospital,Baotou 014010,Inner Mongolia,China)
关键词:
B细胞性非霍奇金淋巴瘤; 利妥昔单抗; 随机对照试验
Keywords:
B-cell non-Hodgkin's lymphoma; Rituximab; Randomized controlled trial
分类号:
R551.2
DOI:
10.3969/j.issn.1006-1959.2019.10.027
文献标志码:
A
摘要:
目的 以Meta分析的方法来评价利妥昔单抗联合CHOP方案治疗B细胞性非霍奇金淋巴瘤的疗效。方法 计算机检索维普数据库、中国知网、万方数据库、pubmed数据库等，检索利妥昔单抗联合化疗治疗B细胞性非霍奇金淋巴瘤的随机对照试验，并手工检索相关会议记录及纸质文献，应用国际Cochrane协作网的系统评价方法对所得数据进行质量评分，进行资料提取后，采用RevMan5.3软件进行Meta分析。结果 共检索到14个随机对照试验，共包括2433例患者，异质性检验P＞0.1，基线具有可比性，选择固定效应模型分析所得结果显示R-CHOP方案化疗组的完全缓解率高于单纯CHOP化疗组（RR=1.3，95%CI为1.3~1.41)，差异有统计学意义（P＜0.05）；R-CHOP方案总有效率高于CHOP组（RR=1.32，95%CI为1.22~1.42），差异有统计学意义（P＜0.05）；其不良反应与对照组比较，差异无统计学意义（P＞0.05）。结论 R-CHOP方案相对CHOP方案治疗B细胞性非霍奇金淋巴瘤来说具有更高的完全缓解率和总有效率，进一步证明其治疗效果需开展更多的随机对照试验。
Abstract:
Objective To evaluate the efficacy of rituximab combined with CHOP regimen in the treatment of B-cell non-Hodgkin's lymphoma by meta-analysis.Methods A computer-based search of the Vip database, China Knowledge Network, Wanfang database, pubmed database, etc., search for randomized controlled trials of rituximab combined with chemotherapy for B-cell non-Hodgkin's lymphoma, and manually retrieve relevant meeting minutes and paper In the literature, the systematic evaluation method of the international Cochrane Collaboration Network was used to score the quality of the data,after data extraction, Meta analysis was performed using RevMan5.3 software.Results A total of 14 randomized controlled trials were included, including a total of 2,433 patients. The heterogeneity test was P>0.1, and the baseline was comparable. The results of the selected fixed-effects model showed that the complete response rate of the R-CHOP regimen was higher than that of CHOP alone. The chemotherapy group (RR=1.3, 95% CI 1.3~1.41), the difference was statistically significant (P<0.05); the total effective rate of R-CHOP regimen was higher than that of CHOP group (RR=1.32, 95% CI was 1.22~1.42),the difference was statistically significant(P<0.05); the adverse reactions were not significantly different from the control group(P>0.05).Conclusion The R-CHOP regimen has a higher complete response rate and total effective rate than the CHOP regimen in the treatment of B-cell non-Hodgkin's lymphoma.It is further proved that the therapeutic effect requires more randomized controlled trials.

参考文献/References:

[1]包维莺,胡喜梅,周水阳,等.非霍奇金淋巴瘤免疫功能的变化及临床意义[J].广西医学,2014,36(12):1703-1705.
[2]Marcus R,Davies A,Ando K,et al.Obinutuzumab for the First-Line Treatment of Follicular Lymphoma[J].N Engl J Med,2017,377(14):1331-1344.
[3]Fowler N,Nastoupil L,de Vos S,et al.Ibrutinib plus rituximab in treatment-naive patients with follicular lymphoma:results from a multicenter,phase 2 study[J].Blood,2015,126(23):470.
[4]Matsumoto K,Takayama N,Aisa Y,et al.A phase Ⅱ study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab:BRB study[J].International Journal of Hematology,2015,101(6):554-562.
[5]Pfreundschuh ML,Trümper L,Osterborg A,et al.CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial(MInT)Group[J].Lancet Oncol,2006,7(5):379-391.
[6]钱海洪,孟海萍,速凤媛,等.利妥昔单抗联合CHOP化疗方案治疗非霍奇金淋巴瘤[J].中国临床医学,2010,17(3):392-393.
[7]Coiffier B,Lepage E,Briere J,et al.CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma[J].N Engl J Med,2002,346(4):235-242.
[8]李俊,苏永强,刘英杰.利妥昔单抗联合CHOP方案治疗初治Ｂ细胞非霍奇金淋巴瘤的疗效观察[J].中国医药科学,2003(13):40-42.
[9]郭丽堃,黎民君,罗华山,等.利妥昔单抗联合CHOP方案治疗Ｂ细胞型非霍奇金淋巴瘤的疗效评价[J].肿瘤药学,2012,2(2):120-122.
[10]汤虎成,曾慧.利妥昔单抗联合CHOP方案治疗非霍奇金淋巴瘤的效果观察[J].中国当代医药,2014(26):101-102,105.
[11]黄泉,季美华,张瑾,等.利妥昔单抗联合CHOP方案治疗Ｂ细胞非霍奇金淋巴瘤疗效观察[J].海南医学,2013,24(19):2824-2827.
[12]邱立丹.利妥昔单抗联合CHOP方案治疗B细胞性非霍奇金淋巴瘤疗效观察[J].中国现代药物应用,2015,9(20):117-118.
[13]HiddemannW,Kneba M,Dreyling M,et al.Frontline therapy with rituximab added to the combinat ion of cylophosphamide,doxorubicin,vinc- ristine,and prednisone(CHOP) significantly improves the outcome for patients with advanced-stage follicular lym- phoma compared with therapy with CHOP alone:Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group[J].Blood,2005(106):3725-3732.
[14]王玮.利妥昔单抗联合CHOP方案治疗B细胞非霍奇金淋巴瘤的疗效分析[J].中南医学科学杂志,2016,44(4):428-431.
[15]Van Oers MH,Klasa R,Marcus RE,et al.Rituximab maintenance improves clinical outcome of relapsed/ref ractory follicular non-Hodgkin lym- phoma in patients both with and without rituximab during induction:Results of a prospective randomized phase 3 inter-group trial[J].Blood,2006,108(10):3295-3301.
[16]徐志巧,刘培杰,高岭美,等.美罗华联合CHOP治疗B细胞性非霍奇金淋巴瘤的临床研究[J].东南大学学报(医学版),2007,26(5):371-373.
[17]李颖,李梅君,廉明.35例利妥昔单抗联合CHOP方案治疗B细胞非霍奇金淋巴瘤的疗效及其安全性[J].中国生化药物杂志,2015,(12):168-170.
[18]林桐榆,张红雨,黄岩,等.R-CHOP与CHOP方案治疗初治弥漫大B细胞型淋巴瘤在中国的多中心随机对照研究[J].癌症,2005,24(12):1421-1426.
[19]Swerdlow SH,Campo E,Pileri SA,et al.The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J].Blood,2016,127(20):2375-2390.
[20]Spina V,Rossi D.Molecular pathogenesis of splenic and nodal marginal zone lymphoma[J].Best Pract Res Clin Haematol,2017,30(1-2):5-12.
[21]Chen J,Kinoshita T,Sukbuntherng J,et al.Ibrutinib inhibits ERBB receptor tyrosine kinases and HER2-amplified breast cancer cell growth[J].Mol Cancer Ther,2016,15(12):2835-2844.
[22]Nabhan C,Zhou X,Day BM,et al.Disease,treatment and outcome differences between men and women with follicular lym- phoma in the United States[J].Am J Hematol,2016,91(8):770-775.
[23]Vargo JA,Gill BS,Balasubramani GK,et al.What is the optimal management of early-stage low-grade follicular lymphoma in the modern era[J].Cancer,2015,121(18):3325-3334.

相似文献/References:

[1]金 英.血浆疗法联合利妥昔单抗治疗初发获得性TTP的效果[J].医学信息,2020,33(07):97.[doi:10.3969/j.issn.1006-1959.2020.07.027]
　JIN Ying.Effect of Plasma Therapy Combined with Rituximab in the Treatment of Newly Acquired TTP[J].Journal of Medical Information,2020,33(10):97.[doi:10.3969/j.issn.1006-1959.2020.07.027]

更新日期/Last Update: 2019-05-15